AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37155342 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib plus PD-1 inhibitor
Number of subjects: 41
Study 37155596 — intervention group
Group type: EXPERIMENTAL
Intervention: HBB Prompt mobile application
Number of subjects: 29
Study 37155596 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBB Prompt)
Number of subjects: 29
Study 37155645 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric, energy-restricted ketogenic diet (KD) for eight weeks
Number of subjects: 0
Study 37155645 — intervention group
Group type: COMPARATOR
Intervention: Standard, balanced diet with the same calorie content
Number of subjects: 0
Study 37155710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthpiece ventilation
Number of subjects: 0
Study 37155710 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37155976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management energy conservation intervention
Number of subjects: 19
Study 37155976 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 19
Study 37156007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative treatment of fractures
Number of subjects: 31
Study 37156249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305 plus chemotherapy (pemetrexed and cisplatin)
Number of subjects: 476
Study 37156249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 476
Study 37156249 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 476
Study 37156249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus IBI305 plus chemotherapy
Number of subjects: 476
Study 37156252 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec
Number of subjects: 582
Study 37156252 — intervention group
Group type: COMPARATOR
Intervention: Once-daily insulin glargine U100
Number of subjects: 582
Study 37156318 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL)
Number of subjects: 61
Study 37156318 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (WLC)
Number of subjects: 61
Study 37156373 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus usual care
Number of subjects: 21
Study 37156373 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 21
Study 37156426 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing (CAMI)
Number of subjects: 149
Study 37156466 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg (up to 100 mg)
Number of subjects: 124
Study 37156466 — intervention group
Group type: COMPARATOR
Intervention: Weight categories (≤90 kg: 40 mg; 91-130 kg: 60 mg; 131-170 kg: 80 mg; >170 kg: 100 mg)
Number of subjects: 124
Study 37156551 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgenic adoptive cell therapy (ACT) with NY-ESO-1-specific TCR transgenic lymphocytes, NY-ESO-1 peptide-pulsed dendritic cell (DC) vaccination, and nivolumab-mediated PD-1 blockade
Number of subjects: 1
Study 37156551 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab-mediated PD-1 blockade
Number of subjects: 1
Study 37156575 — intervention group
Group type: EXPERIMENTAL
Intervention: Citizen Science intervention implemented in intervention schools for 6 months.
Number of subjects: 720
Study 37156575 — intervention group
Group type: COMPARATOR
Intervention: Control group (high schools not receiving the intervention).
Number of subjects: 720
Study 37156577 — intervention group
Group type: EXPERIMENTAL
Intervention: Keeping in Touch (KiT) text message-based intervention
Number of subjects: 183
Study 37156577 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 183
Study 37156585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble-PAPR
Number of subjects: 91
Study 37156585 — intervention group
Group type: COMPARATOR
Intervention: FFP3
Number of subjects: 91
Study 37156587 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based guided hypnotherapy via a website for 3 months (intervention group)
Number of subjects: 200
Study 37156587 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) by their GP (control group)
Number of subjects: 200
Study 37156588 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened antibiotic treatment of 5 days
Number of subjects: 0
Study 37156588 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment of 7 days or longer
Number of subjects: 0
Study 37156670 — intervention group
Group type: EXPERIMENTAL
Intervention: High tissue sodium accumulation
Number of subjects: 83
Study 37156670 — intervention group
Group type: COMPARATOR
Intervention: Non-obese individuals
Number of subjects: 83
Study 37156782 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab, carfilzomib, and dexamethasone (Isa-Kd)
Number of subjects: 302
Study 37156782 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 302
Study 37156960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation in community pharmacy or by phone
Number of subjects: 229
Study 37156960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist consultation)
Number of subjects: 229
Study 37156960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation
Number of subjects: 229
Study 37157110 — intervention group
Group type: EXPERIMENTAL
Intervention: Large change intervention
Number of subjects: 599
Study 37157110 — intervention group
Group type: EXPERIMENTAL
Intervention: Small change intervention
Number of subjects: 599
Study 37157110 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 599
Study 37157126 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 142
Study 37157126 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 142
Study 37158010 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness anxiety (worry about illness, bodily preoccupation)
Number of subjects: 8148
Study 37158010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine willingness
Number of subjects: 8148
Study 37158010 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of the pandemic
Number of subjects: 8148
Study 37158010 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection rates
Number of subjects: 8148
Study 37158010 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher illness anxiety
Number of subjects: 8148
Study 37158042 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality education intervention
Number of subjects: 13
Study 37158083 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy, details not available
Number of subjects: 0
Study 37158104 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate multivessel PCI
Number of subjects: 315
Study 37158104 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only PCI
Number of subjects: 315
Study 37158145 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons experiencing severe complications after radical gastrectomy
Number of subjects: 1062
Study 37158145 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons from non-university affiliated hospitals, junior surgeons, and those facing violent doctor-patient conflicts
Number of subjects: 1062
Study 37158157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED)
Number of subjects: 217
Study 37158157 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator experience
Number of subjects: 217
Study 37158157 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning curve for avoiding major complications
Number of subjects: 217
Study 37158157 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning curve for avoiding poor outcomes
Number of subjects: 217
Study 37158171 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI 0/1-hour algorithm
Number of subjects: 3523
Study 37158171 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI 0/3-hour algorithm
Number of subjects: 3523
Study 37158171 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnI
Number of subjects: 3523
Study 37158171 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 3523
Study 37158245 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdosing via the Optejet
Number of subjects: 0
Study 37158245 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37158538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pharmacologic and psychosocial interventions
Number of subjects: 17626
Study 37158538 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic intervention alone
Number of subjects: 17626
Study 37158538 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial interventions alone
Number of subjects: 17626
Study 37158538 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic in addition to psychosocial intervention
Number of subjects: 17626
Study 37158751 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide (subcutaneously once per week) for 26 weeks
Number of subjects: 5
Study 37158751 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 5
Study 37158780 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual 'Coping with Brain Fog' intervention, details on dosage and duration not available
Number of subjects: 0
Study 37158831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 10 mg/kg for 17 or 26 weeks
Number of subjects: 400
Study 37158831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 15 mg/kg for 17 or 26 weeks
Number of subjects: 400
Study 37158831 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 20 mg/kg for 17 or 26 weeks
Number of subjects: 400
Study 37158831 — intervention group
Group type: COMPARATOR
Intervention: Standardized six-month treatment regimen (rifampicin, isoniazid, pyrazinamide, ethambutol for 26 weeks)
Number of subjects: 400
Study 37158872 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation Matters! mHealth intervention
Number of subjects: 119
Study 37158872 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 119
Study 37158911 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus an oral antidepressant (ESK + AD)
Number of subjects: 223
Study 37158911 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray plus an oral antidepressant (AD + PBO)
Number of subjects: 223
Study 37158925 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics treatment for 12 weeks
Number of subjects: 80
Study 37158925 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 80
Study 37158929 — intervention group
Group type: EXPERIMENTAL
Intervention: General order set improvements
Number of subjects: 0
Study 37158929 — intervention group
Group type: COMPARATOR
Intervention: General order set improvements plus non-interruptive in-line help text alert
Number of subjects: 0
Study 37158929 — intervention group
Group type: COMPARATOR
Intervention: General order set improvements plus interruptive alert
Number of subjects: 0
Study 37158929 — intervention group
Group type: COMPARATOR
Intervention: All arms of the study in aggregate
Number of subjects: 0
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) administered intravenously every 3 weeks
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in NSCLC
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in NPC
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in CC
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in colorectal cancer
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) in small cell lung cancer
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 in immunotherapy-naive patients
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (10 mg/kg) in phase I
Number of subjects: 518
Study 37158938 — intervention group
Group type: EXPERIMENTAL
Intervention: QL1706 (5 mg/kg) overall
Number of subjects: 518
Study 37158965 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-specific HCV treatment workflows utilizing direct-acting antivirals (DAAs) and a simplified treatment algorithm.
Number of subjects: 0
Study 37158965 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews guided by the Practical, Robust Implementation and Sustainability Model (PRISM) framework.
Number of subjects: 0
Study 37158965 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of providers on the use of a simplified HCV treatment algorithm with DAAs.
Number of subjects: 0
Study 37158965 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation and clinical outcomes measured through interviews and medical chart review.
Number of subjects: 0
Study 37158990 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab (Tzield), a monoclonal antibody
Number of subjects: 0
Study 37159034 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ziritaxestat
Number of subjects: 1306
Study 37159034 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of ziritaxestat
Number of subjects: 1306
Study 37159034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1306
Study 37159195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose ingestion (20 g) during a continuous 10-hour sodium d3-acetate intravenous infusion
Number of subjects: 44
Study 37159195 — intervention group
Group type: COMPARATOR
Intervention: OIR group
Number of subjects: 44
Study 37159195 — intervention group
Group type: COMPARATOR
Intervention: Lean group
Number of subjects: 44
Study 37159195 — intervention group
Group type: COMPARATOR
Intervention: OIS group
Number of subjects: 44
Study 37159200 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 80
Study 37159200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 37159245 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-way texting (2wT)
Number of subjects: 1084
Study 37159245 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 1084
Study 37159251 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull energy drink (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Number of subjects: 0
Study 37159251 — intervention group
Group type: COMPARATOR
Intervention: Still water (250 mL administered 2 hours postoperatively and for breakfast and lunch on postoperative day 1, totaling 750 mL per 24 hours)
Number of subjects: 0
Study 37159251 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull energy drink
Number of subjects: 0
Study 37159251 — intervention group
Group type: COMPARATOR
Intervention: Still water
Number of subjects: 0
Study 37159264 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR) 1,000 mg/day
Number of subjects: 25
Study 37159264 — intervention group
Group type: COMPARATOR
Intervention: Coenzyme Q10 (CoQ10) 1,200 mg/day
Number of subjects: 25
Study 37159264 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR)
Number of subjects: 25
Study 37159264 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 25
Study 37159264 — intervention group
Group type: COMPARATOR
Intervention: Nicotinamide riboside (NR) and Coenzyme Q10 (CoQ10)
Number of subjects: 25
Study 37159269 — intervention group
Group type: EXPERIMENTAL
Intervention: THA (Total Hip Arthroplasty)
Number of subjects: 3411
Study 37159269 — intervention group
Group type: COMPARATOR
Intervention: Charnley Class C (multiple-joint OA)
Number of subjects: 3411
Study 37159269 — intervention group
Group type: COMPARATOR
Intervention: Older age
Number of subjects: 3411
Study 37159269 — intervention group
Group type: COMPARATOR
Intervention: Depression
Number of subjects: 3411
Study 37159269 — intervention group
Group type: COMPARATOR
Intervention: Four or more comorbidities
Number of subjects: 3411
Study 37159276 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (approximately 20%) in Responders (n = 11)
Number of subjects: 43
Study 37159276 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (approximately 20%) in Non-responders (n = 11)
Number of subjects: 43
Study 37159276 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (approximately 20%)
Number of subjects: 43
Study 37159610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 177
Study 37160281 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (1.8 × 10^6 or 2.7 × 10^6 doses administered via direct venous inoculation at 8-week intervals)
Number of subjects: 207
Study 37160281 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 207
Study 37160281 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Number of subjects: 207
Study 37160394 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Do Not Do' recommendations with possible gender bias
Number of subjects: 0
Study 37160394 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research techniques (consensus conference and nominal group)
Number of subjects: 0
Study 37160396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ride-on-toy navigation training (RNT) programme, provided 4-5 times/week for 30-45 min/session over 6 weeks, in addition to conventional therapy.
Number of subjects: 15
Study 37160396 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone during the 6-week control phase.
Number of subjects: 15
Study 37160401 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic drugs
Number of subjects: 47106
Study 37160439 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine 123 labeled meta-iodobenzylguanidine
Number of subjects: 40
Study 37160552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-moderate IC group
Number of subjects: 839
Study 37160552 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe IC group
Number of subjects: 839
Study 37160787 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash glucose monitoring (FGM), n=50
Number of subjects: 100
Study 37160787 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG), n=50
Number of subjects: 100
Study 37160808 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y reconstruction
Number of subjects: 0
Study 37160808 — intervention group
Group type: COMPARATOR
Intervention: Classic Roux-en-Y reconstruction
Number of subjects: 0
Study 37160822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management strategies (pain scales, pain diaries, liaison with research team)
Number of subjects: 317
Study 37160822 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational content regarding postoperative care
Number of subjects: 317
Study 37160822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic strategies (acetaminophen and ibuprofen)
Number of subjects: 317
Study 37160822 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication with healthcare providers
Number of subjects: 317
Study 37160822 — intervention group
Group type: EXPERIMENTAL
Intervention: General parental experience
Number of subjects: 317
Study 37160872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 37160872 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A
Number of subjects: 0
Study 37161345 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered computerized mental health screening tool
Number of subjects: 451
Study 37161345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no computerized screening reports)
Number of subjects: 451
Study 37161369 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygenation
Number of subjects: 197
Study 37161369 — intervention group
Group type: COMPARATOR
Intervention: Facemask ventilation
Number of subjects: 197
Study 37161377 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose MR-guided partial breast irradiation (PBI) with a prescribed dose of 20 Gy to the tumor and 15 Gy to the surrounding breast tissue.
Number of subjects: 100
Study 37161377 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose MR-guided partial breast irradiation (PBI)
Number of subjects: 100
Study 37161534 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin treatment
Number of subjects: 55
Study 37161534 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 37161555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition optimisation family-centred intervention
Number of subjects: 135
Study 37161555 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support family-centred intervention
Number of subjects: 135
Study 37161555 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 135
Study 37161571 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline (400-800 mg) and Rifampicin (150-600 mg)
Number of subjects: 17000
Study 37161571 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (150-600 mg)
Number of subjects: 17000
Study 37161571 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin only for contacts aged two to four years
Number of subjects: 17000
Study 37161571 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular surveillance for resistance to rifampicin and/or bedaquiline
Number of subjects: 17000
Study 37161571 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-M. leprae PGL-I IgM seropositivity assessment
Number of subjects: 17000
Study 37161672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Number of subjects: 370
Study 37161672 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis
Number of subjects: 370
Study 37161678 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained premenopausal females
Number of subjects: 42
Study 37161775 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin and high-intensity statin (used in 72.4% of patients)
Number of subjects: 758